Share Prices & Company Research

Stockbroking

Circassia Pharmaceuticals

Current Price 90.80p Bid 90.80p Ask 91.60p Change -2.47%
Last Updated: 27/05/2018 16:54. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Circassia Pharmaceuticals plc is a world-class specialty pharmaceutical business focused on respiratory disease. In addition to its market-leading NIOX products, the Company recently established a collaboration with AstraZeneca in the US in which it promotes the chronic obstructive pulmonary disease (COPD) treatment Tudorza, and has the US commercial rights to late-stage COPD product Duaklir. Circassia's development pipeline includes a range of respiratory medicines. The Company's lead asthma treatment targets substitution of GSK's Flixotide pMDI and was approved in the UK. Circassia is also developing a direct substitute for Seretide pMDI, and its pipeline includes a number of inhaled medicines for COPD, including single and combination dose products.

Financial Highlights Year Ended 31/12/2017

Turnover
£46.30m
Operating Profit
£-121.60m
Dividend Yield
0.00
Dividend Per Share
0.00
Dividend Cover
0.00
P/E Ratio
-3.00

Key Personnel

Steven Charles Andrew Harris
Chief Executive Officer
Julien Fabrice Cotta
Chief Financial Officer
Dr Roderick Peter Hafner
Executive Director
Dr Francesco Granata
Non-Executive Chairman
Jo Susan Le Couilliard
Non-Executive Director
Marvin S Samson
Non-Executive Director
Russell Cummings
Non-Executive Director
Dr Jean-Jacques Garaud
Non-Executive Director
Lota Sue Zoth
Non-Executive Director
Sharon Curran
Non-Executive Director
Dr Heribert Staudinger
Non-Executive Director

Stock Details

EPIC
CIR
ISIN
GB00BJVD3B28
Shares in Issue
333,466,262
Market cap
£310.46m

Analyst Views (3)

Strong Buy
 
33.33%
Buy
 
0.00%
Hold
 
66.67%
Sell
 
0.00%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
90.80p
Bid Price
90.80p
Ask Price
91.60p
Volume
20509
Change Today
-2.30p
% Change Today
-2.47%
Open
93.20p
Previous Close
90.80p
Intraday High
93.20p
Intraday Low
90.80p
52 Week High
113.50p
52 Week Low
76.75p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

Circassia Pharmaceuticals Intra-day Chart

Assets (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Tangible Assets
1.4
1.4
Intangible Assets & Goodwill
209.7
176.8
Investments & Other Non-Current Assets
101.4
17.5
Total Non-Current Assets
312.5
195.7
Inventory
5.0
4.6
Trade & Receivables
18.9
7.7
Cash & Receivables
44.5
97.4
Other Current Assets & Assets Held for Resale
21.5
28.7
Total Assets
402.4
334.1

Liabilities (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Short Term Liabilities
30.8
21.5
Long Term Liabilities
146.8
31.9
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
177.6
53.4

Net Assets (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Net Assets
224.8
280.7

Equity (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Share Capital
0.3
0.2
Minority Interests
0.0
0.0
Retained Earnings
-394.9
-295.8
Share Premium Account
602.2
563.8
Other Equity
17.2
12.5
Total Equity
224.8
280.7

Cashflow (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Cashflow from Operating Activities
-57.6
-56.7
Cashflow Before Financing
-52.4
-69.1
Increase / Decrease in Cash
-54.0
-72.7

Income (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Turnover
46.3
23.1
Cost of Sales
10.0
8.0
Gross Profit
36.3
15.1
Operating Profit
-121.6
-151.5
Pre-Tax Profit
-113.6
-144.9
Profit / Loss for the Year
-99.1
-137.4
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.